Crestor shines for otherwise lacklustre Shionogi
This article was originally published in Scrip
The consolidation of Sciele Pharma in the US and strong growth in royalties for Crestor helped Shionogi overcome an otherwise weak underlying performance in the nine months to December 31st.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.